Technology evaluation: Onyvax-105, Onyvax.
Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000.
Blumenthal
Rosalyn D
RD
Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA. rblumenthal@gscancer.org
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000378:metabolism / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D018958:CD55 Antigens / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D019496:Cancer Vaccines; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D016032:Randomized Controlled Trials as Topic
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018958:CD55 Antigens; D019496:Cancer Vaccines